Clinical trial
Phase II Related or Unrelated Allogeneic Hematopoietic Cell Transplantation for High-Risk Malignancies, Using a Preparative Regimen of Pentostatin (Nipent®) and Alemtuzumab (Campath®)
NCT00698685 is registered in ClinicalTrials.gov with University of Arizona as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Related or Unrelated Allogeneic Hematopoietic Cell Transplantation for High-Risk Malignancies, Using a Preparative Regimen of Pentostatin (Nipent®) and Alemtuzumab (Campath®)
- Lead sponsor
- University of Arizona
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- January 23, 2006
- Completion date
- April 26, 2011
- Enrollment
- 14 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
carcinoma, renal cell, hematologic neoplasms, hodgkin's disease, leukemia, lymphoma, multiple myeloma